NeoGenomics, Inc. (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.
Highlights
Fourth quarter.
Skandinaviska Enskilda Banken AB publ bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,500 shares of the medical research company’s stock, valued at approximately $253,000. Several other institutional investors […]
NeoGenomics, Inc (NASDAQ:NEO) Receives $18 64 Average Target Price from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc. , a leading oncology testing services company, today announced that the Company has signed the Working with Cancer Pledge. By taking the pledge, NeoGenomics demonstrates its.